Basel, Switzerland – Last year’s bet on Google’s passive glucose-sensing contact lens was an important one for the appetite for risk and innovation at Novartis. What started as simple license of a core technology quickly became a pipeline of product possibilities on the platform, including an autofocus feature for people living with presbyopia.
This year, Novartis is making a bolder, more entrepreneurial move by partnering up with the world’s biggest digital health investor, Qualcomm. Together, the two have created a $100 million investment fund to fuel new “beyond the pill” technologies, products and services that will benefit physicians and patients.
The partnership already has two intriguing projects in the works: next generation clinical trials (Trials of the Future) design and an observational pilot of mobile support for people with chronic lung disease. Both bring together in-home monitoring with interesting partnerships, like integration with Walgreen’s Balance Rewards.
These latest moves are building on an intriguing history of digital health trial and innovation at Novartis that’s included partnerships with the ingested-tracker Proteus, health accelerators and competitions, and apps and games.
Detractors might say that digital health is no where near a tipping point. But Novartis is positioned to use its insider knowledge of healthcare to focus on some clever niches who are more than open to innovations in digital health. For example, consider a few headlines from CES:
- Parks Associates released findings that 41% of caregivers use a digital health device
- Family Medicine for America’s Health did a short survey of members of the American Academy of Family Physicians and found that four in 10 use consumer health apps at the point of care
There’s potential for Novartis to reach its goal of “optimizing the value of innovative medicines” through digital support. It just may not be for every patient every time.